JG
TEVA icon

Jefferies Group’s Teva Pharmaceuticals TEVA Stock Holding History

Jefferies Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$2.91M Hold
360,200
– – 0.02% 483
2022
Q2 		$2.71M Hold
360,200
– – 0.02% 522
2022
Q1 		$3.38M Sell
360,200
-727,300
-67% -$6.07M 0.02% 508
2021
Q4 		$8.71M Buy
1,087,500
+100,000
+10% +$903K 0.05% 311
2021
Q3 		$9.62M Hold
987,500
– – 0.07% 272
2021
Q2 		$9.78M Hold
987,500
– – 0.06% 279
2021
Q1 		$11.4M Sell
987,500
-211,600
-18% -$2.43M 0.1% 170
2020
Q4 		$11.6M Buy
1,199,100
+793,300
+195% +$7.6M 0.09% 187
2020
Q3 		$3.66M Hold
405,800
– – 0.04% 363
2020
Q2 		$5K Buy
405,800
+119,200
+42% +$1.35M 0.06% 274
2020
Q1 		$2.57M Hold
286,600
– – 0.03% 559
2019
Q4 		$2.81M Buy
+286,600
New +$2.56M 0.02% 845
2019
Q3 		– Sell
-22,500
Closed -$208K – 3040
2019
Q2 		$208K Sell
22,500
-77,500
-78% -$934K ﹤0.01% 2120
2019
Q1 		$1.57M Sell
100,000
-17,100
-15% -$302K 0.01% 1039
2018
Q4 		$1.81M Buy
117,100
+100,000
+585% +$2.05M 0.01% 867
2018
Q3 		$368K Sell
17,100
-140,400
-89% -$3.26M ﹤0.01% 1768
2018
Q2 		$3.83M Buy
157,500
+87,500
+125% +$1.78M 0.02% 608
2018
Q1 		$1.2M Buy
+70,000
New +$1.37M 0.01% 1121
2017
Q3 		– Sell
-100,000
Closed -$3.32M – 2612
2017
Q2 		$3.32M Buy
+100,000
New +$3.1M 0.02% 722
2016
Q4 		– Sell
-28,400
Closed -$1.31M – 2473
2016
Q3 		$1.31M Buy
+28,400
New +$1.48M 0.01% 1151
2016
Q1 		– Sell
-234,800
Closed -$15.4M – 2550
2015
Q4 		$15.4M Buy
234,800
+184,800
+370% +$11.4M 0.09% 180
2015
Q3 		$2.82M Buy
50,000
+43,200
+635% +$2.8M 0.02% 736
2015
Q2 		$402K Buy
+6,800
New +$419K ﹤0.01% 1665
2014
Q2 		– Sell
-221,100
Closed -$11.7M – 2374
2014
Q1 		$11.7M Buy
221,100
+44,800
+25% +$2.07M 0.11% 149
2013
Q4 		$7.07M Buy
+176,300
New +$6.94M 0.04% 236

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Jefferies Group's TEVA Position: Q3 2022 in Review

Jefferies Group reduced its Teva Pharmaceuticals (TEVA) stake by 6.2% in Q3 2022, selling an estimated $150K and leaving 258,664 shares worth $2.09M. The position accounts for 0.02% of the portfolio, ranked #591.

Jefferies Group first reported a position in TEVA in Q3 2013 and has held it in 32 quarters since. The position peaked at $72.6M in Q1 2015. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

  • Jefferies Group held 258,664 shares of Teva Pharmaceuticals worth $2.09M as of Q3 2022.
  • Jefferies Group sold 16,965 Teva Pharmaceuticals shares in Q3 2022, an estimated $150K.
  • Teva Pharmaceuticals made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #591 holding.
  • Jefferies Group first reported a position in Teva Pharmaceuticals in Q3 2013 and has held it in 32 quarters since.
  • Jefferies Group's Teva Pharmaceuticals position peaked at $72.6M in Q1 2015.
  • 430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.